Blockade of the serotonin and norepinephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain

K Kasamo, P Blier and C De Montigny

Neurobiological Psychiatry Univ, McGill University, Montreal, Quebec,Canada.

In in vitro uptake experiments, duloxetine inhibited [3H]5- hydroxytryptamine (5-HT) and [3H]norepinephrine (NE) uptake in hippocampus slices of control rats with IC50 values of 28 and 46 nM, respectively. The uptake of both[3H]5-HT and [3H]NE was equipotently inhibited in hippocampus slices prepared from rats treated for 2 days with different doses of duloxetine (5, 10, 15 and 20 mg/kg/day s.c.). In in vivo electrophysiological experiments in the hippocampus, the effects of duloxetine on the suppression of CA3 pyramidal neuronal firing activity by microiontophoretically applied 5-HT and NE were examined with two modes of administration. Five successive i.v. injections (2 mg/kg each) significantly and dose-dependently prolonged the recovery time of the firing activity of hippocampus CA3 pyramidal neurons from the 5-HT applications. A 2-day treatment (10, 15 and 20 mg/kg/day s.c.) also increased the recovery time in a dose-dependent manner. Whereas the recovery time from NE applications was unaffected by low doses of duloxetine (2 mg/kg i.v.; 10 mg/kg/day for 2 days), it was prolonged significantly by higher doses (8 and 1 0 mg/kg iv.; 20 mg/kg/day for 2 days). Acute i.v. injections of duloxetine suppressed the spontaneous firing activity of dorsal raphe 5-HT and locus ceruleus NE neurons with ED50 values of 99 and 475 microgram/kg, respectively. Taken together, the present results confirmed that duloxetine is a dual 5-HT/NE uptake inhibitor. Furthermore, the results obtained in in vivo experiments indicate that duloxetine has a preferential inhibitory effect on the 5-HT transporter.

Volume 277, Issue 1, pp. 278-286, 04/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				P. M. Vis, M. van Baardewijk, and T. R Einarson Duloxetine and Venlafaxine-XR in the Treatment of Major Depressive Disorder: A Meta-Analysis of Randomized Clinical Trials Ann. Pharmacother., November 1, 2005; 39(11): 1798 - 1807. [Abstract] [Full Text] [PDF]

				J. Angulo, P. Cuevas, B. Cuevas, S. Gupta, and I. S. de Tejada Mechanisms for the Inhibition of Genital Vascular Responses by Antidepressants in a Female Rabbit Model J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 141 - 149. [Abstract] [Full Text] [PDF]

				G. Pineyro and P. Blier Autoregulation of Serotonin Neurons: Role in Antidepressant Drug Action Pharmacol. Rev., September 1, 1999; 51(3): 533 - 591. [Abstract] [Full Text] [PDF]

				L. E. Rueter, C. De Montigny, and P. Blier Electrophysiological Characterization of the Effect of Long-Term Duloxetine Administration on the Rat Serotonergic and Noradrenergic Systems J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 404 - 412. [Abstract] [Full Text]